STOCKS TELEGRAPH

Tag: Alzheimers

  • Alterity Therapeutics Ltd. (ATHE) Stock Surges as Scope of Patent is Explored in Treatment of Alzheimer’s and Parkinson’s

    Alterity Therapeutics Ltd. (ATHE) stock prices were down by 2.11%, bringing the price per share down to USD$1.39 at the end of the trading day. Subsequent premarket fluctuations saw the stock surge by 30.22%, bringing it up to USD$1.81.

    USPTO Patent

    July 1st, 2021 saw the company announce that it had been granted a new composition of matter patent by the United States Patent and Trademark Office (USPTO). This patent will offer the company a vast monopoly over a new class of iron chaperons, which is a technology capable of redistributing excess iron in the central nervous system. The structural backbone presented in the patent serves as the foundation for small molecule drug candidates that have the capacity to cross the blood brain barrier, thus directly attacking sources of various neuropathologies.

    Scope of Patent

    Alzheimer’s and Parkinson’s are associated with excess levels of iron in the brain, as are various other important neurodegenerative diseases. Titled “Compounds for and Methods of Treating Diseases”, the patent was granted following an expedited review by the USPTO. It includes coverage of more than 150 novel pharmaceutical compositions that are designed to facilitate the redistribution of the labile iron that is involved in a myriad of neurodegenerative conditions.

    Dissecting the Patent

    The company is set to launch the Phase 2 trial of ATH434, its lead clinical candidate, by the end of the 2021 year. The small molecule drug is being developed for Multiple System Atrophy (MSA), which is a form of atypical parkinsonism where iron is essential in pathogenesis by promoting α-synuclein aggregation. Results from the Phase 2 study, in conjunction with the ongoing scientific investigation of the treatment, will facilitate the development and optimization of novel compounds that are expected to emerge from the new patent

    Continued Expansion

    The significant milestone represents an important part of our corporate strategy aimed to expand the company’s portfolio of potential disease modifying treatments for the demographic affected by neurodegenerative diseases. The newly covered compounds are designed to target excess brain iron resulting from the conditions, with the company hoping to identify a new clinical candidate by the time the lead clinical program results are reported.

    Future Outlook for ATHE

    Armed with the lucrative potential afforded by the granting of the patent, ATHE is poised to capitalize on the continued development of its lead product. The company is keen to continue its trajectory of success as it continues to explore added opportunities arising from the patent. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to usher in significant and sustained increases in shareholder value.

  • Synaptogenix, Inc. (SNPX) Stock Skyrockets as Latest Potential Target of Reddit-Driven Meme Stock Phenomenon

    Synaptogenix, Inc.(SNPX) stock prices skyrocketed by a massive 20.80% shortly after market trading commenced on June 17th, 2021, bringing the price per share up to USD$10.75 early on in the trading day.

    Meme Stock Phenomenon

    SNPX could be the latest in a series of stocks that have been picked up by Reddit-driven retail investors tat are responsible for the recent resurgence of the meme stock phenomenon. Underdogs with high short interests find themselves fortuitously bolstered as the community of investors continues to target companies without a logical basis for their support. In the absence of recent news or any fundamental developments, companies sometimes on the brisk of collapse find themselves renewed by the sweeping meme stock craze.

    Securities Purchase Agreement

    The up-and-coming biopharmaceutical company recently announced the successful execution of a securities purchase agreement, wherein SNPX hopes to generate gross proceeds in the amount of USD$12.5 million. The private placement financing of common stock and warrants will comprise holistic units, which will be sold off in the placement that will be primarily led by existing institutional shareholders.

    Allocation of Funds

    Capital generated from the net proceeds of the private placement are forecasted to be allocated towards the supporting of the ongoing development of Brystatin-1. The treatment is currently in Phase 2b of a NIH-sponsored Alzheimer’s disease trial, with further research and development being carried out to facilitate new indications.

    Unit Composition

    Each unit being sold in the offering consists of a single share of SNPX’s common stock combined with one warrant, with a combined purchase price of USD$7.547 per unit. The warrants have an exercise date of five years from when they are issued, and are priced at USD$8.51 per share of common stock. The placement was scheduled to close the same day, on June 16th 2021.

    Future Outlook for SNPX

    Armed with a solid liquidity position from their recent offering, SNPX is undoubtedly delighted with the skyrocketing of their equity value despite a stark absence of media coverage of significant motivators of that stock movement. The company is keen to continue its trajectory of success to usher in more organic growth. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.